

Company Registration No. 4217656

Summit Pharmaceuticals Europe Limited

Report and Financial Statements

31 March 2012

MONDAY



L1BTIN0Q

LD4

25/06/2012

#18

COMPANIES HOUSE

Summit Pharmaceuticals Europe Limited

Report and financial statements 2012

Contents	Page
Directors' report	1
Statement of directors' responsibilities in respect of the Directors Report and the financial statements	4
Independent auditor's report to the members of Summit Pharmaceuticals Europe Limited	5
Profit and loss account	6
Reconciliation of movements in equity shareholders' funds	7
Balance sheet	8
Notes to the accounts	9

Summit Pharmaceuticals Europe Limited

Directors' report

The directors present their annual report and the audited financial statements for the year ended 31 March 2012

Principal activities

The company trades in pharmaceutical products, selling to the United Kingdom, European and other markets. The company operates in London, Milan and Madrid.

Business review

There have not been any significant changes in the company's principal activities in the year under review.

For the year ended 31 March 2012, the company made a profit after tax of €646,000 (2011: €514,000). Turnover increased to €4,487,000 (2011: €3,943,000) and Gross Trading Profit margin increased from 9.5% to 12.4%.

The balance sheet shows an increase in net assets of €389,000. As a result of the performance and transactions during the year, the company decreased amounts owed to trade creditors and group companies by €1,876,000. Debtors have decreased from €10,159,000 to €8,925,000, also due to the performance and transactions during the year.

Sumitomo Corporation manages its operations in Europe on a regional basis. For this reason, the company's directors believe that key performance indicators for the company are not necessary or appropriate for an understanding of the development, performance or position of the business. The performance of the European division of Sumitomo Corporation, which includes this company, is discussed in the global group's Annual Report which does not form part of this report.

Principal risks and uncertainties

The current economic climate has created an uncertainty in the world's financial and commodity markets. This uncertainty is difficult to quantify in terms of its impact on the company's financial results. However, the company has a diversified client base to meet the uncertainties of the future.

Competitive pressures in the European operating environment provide a continuing risk to the company, which could result in loss of business to its competitors. The key factor for the company in managing this risk is to maintain and enhance the close relationships with its customers and suppliers.

Foreign exchange risk

The company operates in a multi-currency environment and is therefore exposed to currency risks arising from the movement between its principal trading currencies of US Dollar, GBP and Japanese Yen and its reporting currency Euro. The company manages these risks by entering into forward exchange contracts through a back to back contract with its fellow subsidiary, Sumitomo Corporation Europe Limited.

Liquidity and Cash risk

To manage cash and liquidity the company operates a central pooling of bank balances of all of its branches across Europe to the Head Office. Cash and liquidity is managed in conjunction with its fellow group company, Sumitomo Corporation Europe Limited, based in London, England.

Summit Pharmaceuticals Europe Limited

Directors' report (continued)

Credit risk

The company's principal financial assets are bank balances and cash, trade and other receivables

The company's credit risk is primarily attributable to its trade receivables. The amounts presented in the balance sheet are net of allowances for doubtful receivables. An allowance for impairment is made where there is an identified loss event which, based on previous experience, is evidence of a reduction in the recoverability of the cash flows.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by international credit-rating agencies.

The company places a high importance on risk management and in ensuring that the company's customers and vendors have a sound financial base. The current economic problems in the financial and commodity markets have not led to an increase in the bad debts incurred by the company.

Price risk

The company monitors changes in commodity prices on a continual basis to ensure that the company maintains control over its gross trading profit and inventory value.

Employees

Details of the number of employees and related costs can be found in note 4 to the financial statements.

The company participates in the group's policies and practices to keep employees informed on matters relevant to them as employees through regular meetings and newsletters. Employees are consulted regularly on a wide range of matters affecting their interests.

The company is committed to giving full and fair consideration to applications for employment from people with disabilities and to continuing the employment of staff who become disabled, and arranging appropriate training to achieve this.

Dividends

The company paid a dividend in the year of €257,000 (2011: € Nil) in respect of profits achieved up to and including the year ended 31 March 2012.

Directors

The directors who held office during the year were as follows:

Y Tanaka (Resigned 25 July 2011)
K Nakamura (Appointed 12 April 2011)
N Sone
T Suto
T Horimoto
T Sato (Resigned 30 April 2011)
T Izuta (Appointed 30 April 2011)

Directors' indemnities

The company has granted an indemnity to its directors against liability in respect of proceedings brought by third parties, subject to the conditions set out in section 234 of the U.K. Companies Act 2006. Such qualifying third party indemnity provision remains in force as at the date of approving the directors' report.

Political and charitable contributions

The Company made no political or charitable donations or incurred any political expenditure during the year (2011: Nil).

Summit Pharmaceuticals Europe Limited

Directors' report (continued)

Disclosure of information to auditor

The directors who held office at the date of approval of this directors' report confirm that, so far as they are each aware, there is no relevant audit information of which the Company's auditor is unaware, and each director has taken all the steps that he/ she ought to have taken as a director to make himself/ herself aware of any relevant audit information and to establish that the company's auditor is aware of that information

Auditor

Pursuant to Section 487 of the Companies Act 2006, the auditor will be deemed to be reappointed and KPMG Audit Plc will therefore continue in office

By order of the board



T Izuta
Director
21 June 2012

Vintners' Place
68 Upper Thames Street
London EC4V 3BJ

Summit Pharmaceuticals Europe Limited

Statement of directors' responsibilities in respect of the Directors Report and the financial statements

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with UK Accounting Standards and applicable law (UK Generally Accepted Accounting Practice)

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgments and estimates that are reasonable and prudent,
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements, and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.

Independent auditor's report to the members of Summit Pharmaceuticals Europe Limited

We have audited the financial statements of Summit Pharmaceutical Europe Limited for the year ended 31 March 2012 set out on pages 6 to 19. The financial reporting framework that has been applied in their preparation is applicable law and UK Accounting Standards (UK Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditor

As explained more fully in the Directors' Responsibilities Statement set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit, and express an opinion on, the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the APB's web-site at www.frc.org.uk/apb/scope/private.cfm

Opinion on financial statements

In our opinion the financial statements

- give a true and fair view of the state of the company's affairs as at 31 March 2012 and of its profit for the year then ended,
- have been properly prepared in accordance with UK Generally Accepted Accounting Practice, and
- have been prepared in accordance with the requirements of the Companies Act 2006


Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us, or
- the financial statements are not in agreement with the accounting records and returns, or
- certain disclosures of directors' remuneration specified by law are not made, or
- we have not received all the information and explanations we require for our audit



Kevin Hall
Senior Statutory Auditor
for and on behalf of KPMG Audit Plc, Statutory Auditor
Chartered Accountants
15 Canada Square
London E14 5GL
United Kingdom
21 June 2012

Summit Pharmaceuticals Europe Limited

Profit and loss account for the Year ended 31 March 2012

	Notes	2012 €'000	2011 €'000
Turnover	2	4,487	3,943
Administrative expenses		(3,503)	(3,053)
Operating profit	5	<u>984</u>	<u>890</u>
Interest receivable and similar income	6	42	24
Interest payable and similar charges	7	(26)	(20)
Loss on disposal of fixed assets		-	(3)
Profit on ordinary activities before taxation		<u>1,000</u>	<u>891</u>
Tax on profit on ordinary activities	8	<u>(354)</u>	<u>(377)</u>
Profit on ordinary activities after taxation for the financial year		<u><u>646</u></u>	<u><u>514</u></u>

The company also undertakes transactions which in substance are agency and not principal. The value of these transactions amounted to €36,100,000 (2011: €41,966,000) gross turnover. The net value of these transactions is included as Turnover above.

There are no recognised gains or losses for the current or prior year other than those shown in the profit and loss account.

Notes on pages 9 to 18 form part of the Financial Statements.

Summit Pharmaceuticals Europe Limited

Reconciliation of movements in shareholders' funds Year ended 31 March 2012

	2012 €'000	2011 €'000
Profit for the year	646	514
Dividends paid	(257)	-
Net increase in shareholders' funds	389	514
Opening shareholders' funds	3,294	2,780
Closing shareholders' funds	3,683	3,294

Summit Pharmaceuticals Europe Limited

Balance sheet


As at 31 March 2012

		2012	2011
	Note	€'000	€'000
Fixed assets			
Tangible assets	9	145	176
Investment	10	10	-
		<u>155</u>	<u>176</u>
Current assets			
Stocks	11	276	409
Debtors	12	8,925	10,159
Derivative Assets	18	12	121
Cash at bank and in hand		193	119
		<u>9,406</u>	<u>10,808</u>
Creditors: amounts falling due within one year			
Trade creditors	13	2,873	4,170
Amounts owed to group undertakings	13	2,010	2,573
Derivative Liabilities	18	2	98
Other creditors including taxation and social security	14	300	262
Accruals and deferred income		449	371
		<u>5,634</u>	<u>7,474</u>
Net current assets		<u>3,772</u>	<u>3,334</u>
Total assets less current liabilities		<u>3,927</u>	<u>3,510</u>
Provision for liabilities	15	(244)	(216)
Net assets		<u>3,683</u>	<u>3,294</u>
Capital and reserves			
Called up share capital	19	2,399	2,399
Profit and loss account	20	1,284	895
Shareholders' funds		<u>3,683</u>	<u>3,294</u>

Notes on pages 9 to 18 form part of the Financial Statements

These financial statements were approved by the Board of Directors on 21 June 2012

Signed on behalf of the Board of Directors



T Izuta
Director

Company registered number 4217656

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

1. Accounting policies

The financial statements are prepared in accordance with applicable United Kingdom law and accounting standards. The particular accounting policies adopted are described below. They have all been applied consistently throughout the current and the preceding year.

Accounting convention

The financial statements are prepared on the historical cost and going concern basis except for the following:

- derivative financial instruments are measured at fair value
- financial instruments at fair value through profit and loss are measured at fair value

Tangible fixed assets

Tangible fixed assets are stated at cost net of depreciation and any provisions for impairment. Depreciation is provided against cost in equal annual instalments over the estimated useful life of the asset. The rates of depreciation generally in use are as follows:

Plant and machinery	10%-33% per annum
Fixtures and fittings	10%-33% per annum

Investments

Investments held as fixed assets are stated at cost less any provision required for impairment.

Stocks

Stocks are stated at the lower of cost and net realisable value. Cost represents invoiced price together with, as appropriate, directly related overheads. Net realisable value is based on estimated selling price, less further costs expected to be incurred to disposal. Provision is made for obsolete, slow-moving or defective items where appropriate.

Turnover

Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

Turnover represents the gross sales value achieved by the company when acting as a principal together with commissions and service fees receivable. The factors which determine whether a transaction is recorded as gross or net include who carries the risk of inventory or credit risk, who fixes the contract price and product specification, whether there is payment of fixed commission to the company. The gross contract values where the company does not act as a principal are excluded from turnover and cost of sales to reflect the substance of these transactions.

Sales of goods are recognised when goods are delivered and title has passed.

Taxation

Current tax, including UK corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using tax rates and laws that have been enacted by the balance sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date. Timing differences are differences between the company's taxable profits and its results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in periods different from those in which they are recognised in the financial statements.

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

1. Accounting policies (continued)

A net deferred tax asset is regarded as recoverable and therefore recognised only when, on the basis of all available evidence, it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted. Deferred tax assets and liabilities are not discounted.

Financial Instruments

Financial assets and financial liabilities are recognised in the company's balance sheet when the company becomes a party to the contractual provisions of the instrument.

The company has taken advantage of the disclosure exemptions in FRS29 Financial Instruments Disclosures and has therefore not included such disclosures in these financial statements on the basis that they will be provided on a consolidated basis on the consolidated financial statements of the ultimate parent company, Sumitomo Corporation, which is incorporated in Japan.

Trade receivables

Trade receivables are measured at initial recognition at cost. Appropriate allowances for estimated irrecoverable amounts are recognised in profit or loss when there is objective evidence that the asset is impaired. The allowance recognised is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the effective interest rate computed at initial recognition.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and demand deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value.

Bank borrowings

Interest-bearing bank loans and overdrafts are recorded at the proceeds received, net of direct issue costs. Finance charges, including premiums payable on settlement or redemption and direct issue costs, are accounted for on an accrual basis in profit or loss using the effective interest rate method and are added to the carrying amount of the instrument to the extent that they are not settled in the period in which they arise.

Trade payables

Trade payables are initially measured at fair value, and are subsequently measured at amortised cost, using the effective interest rate method. All transactions are recognised on their transaction date.

Foreign exchange

Transactions in currencies other than the entity's functional currency are recorded using the rate of exchange ruling at the date of the transaction or, if hedged forward, at the rate of exchange under the related forward currency contract. Monetary assets and liabilities denominated in foreign currencies are translated using the contracted rate or the rate of exchange ruling at the balance sheet date and the gains or losses on translation are included in the profit and loss account.

Derivatives

The company uses derivative financial instruments such as foreign exchange forward contracts to hedge its risk associated with foreign exchange fluctuations. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value, through the profit and loss account. Derivatives are carried as assets when the fair value is positive and as liabilities when the fair value is negative.

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

1 Accounting policies (continued)

Related parties

The company has taken advantage of the disclosure exemptions in FRS8 Related Parties and therefore has not disclosed details of transactions with group companies in these financial statements

Cash flow statement

The company has taken advantage of the exemption offered by FRS1 Cash Flow Statements not to prepare a cash flow statement on the basis that the ultimate parent company produces consolidated accounts, which include a cashflow statement, into which the company's accounts are fully consolidated

Pension costs

For defined contribution schemes the amount charged to the profit and loss account in respect of pension costs and other post-retirement benefits is the contributions payable in the year. Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments in the balance sheet

2. Turnover

Turnover represents amounts derived from the provision of goods and services which fall within the company's ordinary activities after deduction of trade discounts, value added tax and other sales related taxes. The turnover/revenue is attributable to one activity, the trading of pharmaceutical products. In the opinion of the directors, it is seriously prejudicial to the interests of the company and not meaningful to give an analysis of turnover/revenue by geographical area.

The gross value of trades where the company acts as an agent during the year is €36,100,000 (2011 €41,966,000), with associated cost of sales €31,613,000 (2011 €38,023,000)

3. Remuneration of directors

	2012 €'000	2011 €'000
Directors' Emoluments	320	480
No pension contributions were made in respect of Directors		
Remuneration of highest paid director	261	480

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

4. Staff numbers and costs

	2012 €'000	2011 €'000
Employee costs during the year (including directors)		
Wages and salaries	1,553	1,118
Social security costs	217	189
Other pension costs	55	46
	<u>1,825</u>	<u>1,353</u>
	No.	No.
Average number of persons employed	<u>14</u>	<u>14</u>

5. Operating profit

	2012 €'000	2011 €'000
Profit on ordinary activities before tax is after charging		
Depreciation	38	36
Net loss/(gain) on exchange differences	165	(32)
	<u>80</u>	<u>75</u>
Auditors' remuneration – audit of these financial statements		
	<u>80</u>	<u>75</u>

Other amounts receivable by the company's auditor in respect of services to the company other than the audit of the company's financial statements are €1,385 00 in total and relate to iXBRL tagging of 2011 statistics, referencing the online corporate tax submission for 2011

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

6 Interest receivable and similar income

	2012 €'000	2011 €'000
Bank deposit interest	4	7
Interest receivable from group companies	38	17
	<u>42</u>	<u>24</u>

7. Interest payable and similar charges

	2012 €'000	2011 €'000
Interest payable to group companies	26	20
	<u>26</u>	<u>20</u>

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

8 Tax on profit on ordinary activities

(a) Analysis of charge in year:

	2012 €'000	2011 €'000
Current tax		
UK corporation tax on profits of the year	23	-
Foreign tax	351	354
Adjustment to tax charge in respect to previous period	2	14
	<u>376</u>	<u>368</u>
Total current tax	376	368
Deferred tax		
Origination and reversal of timing differences	(22)	9
	<u>(22)</u>	<u>9</u>
Tax charge on profit on ordinary activities	<u>354</u>	<u>377</u>

(b) Factors affecting tax for the year

The tax assessed for the year is higher (2011 higher) than the standard rate of corporation tax in the UK of 26% (2011 28%). The differences are explained below

	2012 €'000	2011 €'000
Profit on ordinary activities before tax	<u>1,000</u>	<u>891</u>
Tax at 26% (2011 28%) thereon	260	249
Effects of		
Expenses not deductible for tax purposes	19	20
Capital allowances in period in excess of depreciation	0	2
Overseas tax rates	95	83
Gains on sale of investment	0	-
Adjustment to tax charge in respect to previous period	2	14
	<u>376</u>	<u>368</u>
Current tax charge for year	<u>376</u>	<u>368</u>

(c) Factors affecting the tax charge for future periods

The 2012 Budget on 21 March 2012 announced that the UK corporation tax rate will reduce to 22% by 2014. A reduction in the rate from 26% to 25% (effective from 1 April 2012) was substantively enacted on 5 July 2011, and a further reduction to 24% (effective from 1 April 2012) was substantively enacted on 26 March 2012. This will reduce the company's future current tax charge accordingly. It has not yet been possible to quantify the full anticipated effect of the announced further 2% rate reduction, although this will further reduce the company's future current tax charge and reduce the company's deferred tax asset accordingly.

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

9. Fixed assets

	Building & structure €'000	Plant and machinery €'000	Fixtures and fittings €'000	Total €'000
Cost				
At 1 April 2011	84	176	58	318
Additions	-	5	2	7
Disposals	-	(17)	-	(17)
At 31 March 2012	84	164	60	308
Accumulated depreciation				
At 1 April 2011	14	103	25	142
Charge for the year	14	20	4	38
Disposals	-	(17)	-	(17)
At 31 March 2012	28	106	29	163
Net book value				
At 31 March 2012	56	58	31	145
At 31 March 2011	70	73	33	176

10. Investments

	2012 Other investment (unlisted) €'000	2011 Other investment (unlisted) €'000
Cost and net book value	10	-

The company holds one share in Immobiliare Golf Castel Conturbia SpA, located in Agrate Conturbia, Novara, Italy

11. Stocks

	2012 €'000	2011 €'000
Finished goods and goods for resale	276	409

The replacement cost of stocks held by the company at 31 March 2012 was not significantly different from the amount at which it is stated in the balance sheet

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

12. Debtors

	2012 €'000	2011 €'000
Trade debtors	4,195	4,851
Amounts owed by group undertakings	4,483	4,765
Other debtors	17	11
Deferred tax	13	-
Prepayments and accrued income	217	532
	<u>8,925</u>	<u>10,159</u>

The average credit period taken on sales of goods is 88 days (2011 84 days) This is calculated using the gross value of transactions for agency sales The gross value of trades where the company acts as an agent during the year is €36,100,000 (2011 €41,966,000)

No interest is charged on the receivable from the date of invoicing until the due date of payment Directors consider the carrying amount of trade and other debtors approximates their fair value

13. Trade creditors and Amounts owed to group undertakings

	2012 €'000	2011 €'000
Trade creditors	<u>2,873</u>	<u>4,170</u>
Amounts owed to group undertakings	<u>2,010</u>	<u>2,573</u>

Trade creditors and amounts owed to group undertakings principally comprise amounts outstanding for trade purchases and ongoing costs The average credit period taken for trade purchases is 56 days (2011 65 days) This is calculated on gross cost of sales The gross value of cost of sales where the company acts as an agent during the year is €31,613,000 (2011 €38,023,000)

14. Other creditors including taxation and social security

	2012 €'000	2011 €'000
Other creditors	74	(9)
Corporation tax	189	234
Deferred tax	-	9
Other taxation and social security costs	<u>37</u>	<u>28</u>
	<u>300</u>	<u>262</u>

For notes 13 and 14 the directors consider the carrying amount of trade and other creditors approximates their fair value

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

15. Provision for liabilities

	2012 €'000	2011 €'000
Employee's retirement allowance (TFR)	244	216
	€'000	€'000
Opening balance	216	204
Charge to profit and loss account	39	39
Transfer out of funds for leavers	(11)	(27)
Closing balance	244	216

Employees' retirement allowance

Under Italian law the company is required to maintain a Trattamento Fine Rapporto (TFR) for its employees. The cost to the company in cash terms during the year was €48,000 (2011: €46,000).

16. Deferred taxation

The amounts of deferred taxation provided in the accounts are

	2012 €'000	2011 €'000
Short term timing differences	(13)	9
Opening balance	9	-
Charged to profit and loss account	(22)	9
Closing balance	(13)	9

In accordance with FRS 19 Deferred Tax, the company provides for all deferred tax liabilities in full less available deferred tax assets. Milan branch booked deferred tax assets and liabilities at a rate of 27.5% (2011: 27.5%). Madrid and London branches had no deferred tax bookings in both years.

17. Pension costs

The company operated a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to €6,000 (2011: € nil).

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

18. Derivative financial instruments

Currency derivatives

	2012 \$'000	2011 \$'000
Derivative asset	12	121
Derivative liability	(2)	(98)

The company does not currently designate its foreign currency denominated debt as a hedging instrument for the purpose of hedging the translation of its foreign operations

The company is a party to a variety of foreign currency forward contracts and options in the management of its exchange rate exposures. The instruments purchased are primarily denominated in the currencies of the company's principal markets.

At the balance sheet date, total fair value amount of outstanding forward foreign exchange contracts that the company has committed are as below

	2012 \$'000	2011 \$'000
Forward foreign currency contracts	10	23

The notional value of the forward foreign currency contracts is

	Buy 000's	Sell 000's
JPY	191,697	182,461
USD	2,509	4,318

The fair value is calculated using the rates obtained from Bloomberg on the last trading day of the year

Summit Pharmaceuticals Europe Limited

Notes to the accounts

(forming part of the financial statements)

19. Called up share capital

	2012 €'000	2011 €'000
Called up, allotted and fully paid:		
1,614,000 ordinary shares of £1 each	2,399	2,399

The value of the company's £1 shares translated at the closing rate at 31 March 2012 is €1,936,000 (2011 €1,826,000)

20. Profit and loss account

	2012 €'000	2011 €'000
Balance brought forward	895	381
Profit retained for year	646	514
Dividend paid	(257)	-
Balance carried forward	1,284	895

21. Dividends paid

	2012 \$'000	2011 \$'000
Dividend paid	257	-

22. Parent company

The parent company is Sumitomo Corporation, a company incorporated in Japan, which owns 51% of the share capital. The remaining shareholding is owned by Sumitomo Corporation Europe Limited, a company incorporated in England.

Sumitomo Corporation heads the largest group of which the company is a member and for which group accounts are prepared. The group accounts for Sumitomo Corporation are available at 8-11 Harumi, 1-chome, Chuo-ku, Tokyo, Japan.